Editorial introductions

Abstract

Current Opinion in Infectious Diseases was launched in 1988. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of infectious diseases is divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. SECTION EDITORS Monica A. SlavinMonica A. SlavinMonica A. Slavin MBBS, FRACP, MD, is based in Melbourne, Australia, where she has been Head of the Department of Infectious Diseases at the Peter MacCallum Cancer Centre since 2000 and Head of the Immunocompromised Host Service at Royal Melbourne Hospital since 2013. She is a Professor in the Department of Medicine at the University of Melbourne, Australia and a Research Associate at the Macfarlane Burnet Centre for Medical Research and Public Health, Australia. Professor Slavin received her medical degree from the University of Melbourne, Australia and trained in infectious diseases in Melbourne and in the program in infectious diseases at Fred Hutchison Cancer Research Center in Seattle, USA. She has been an infectious diseases physician since 1993 with a major interest in infections in immunocompromised patients, especially those with cancer and undergoing stem cell transplantation. Her current research focus is prevention diagnosis and early treatment of invasive fungal infections in haematology patients. She has served on national steering committees for the development of antifungal and fever and neutropenia treatment guidelines and for the conduct of Australia-wide studies of the epidemiology of fungal infection. She is chair of the Australian & New Zealand Mycoses Interest Group and is the lead author of the Australasian Society for Infectious Diseases (ASID) guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. She is a councillor of the International Immunocompromised Host Society. Deenan PillayDeenan PillayFollowing a PhD in Biochemistry, Professor Pillay studied Medicine in Newcastle upon Tyne, UK, and undertook postgraduate training in medical virology at St Thomas's Hospital and Royal Free Hospital, London, UK, followed by an National Institute of Health (NIH) fellowship in the laboratory of Dr Doug Richman, University of California, San Diego, USA, where he developed an interest in HIV Drug Resistance. On his return to the UK, Professor Pillay took up the post of Consultant Medical Virologist, Birmingham Public Health Laboratory, UK, and in 1996 became Director of the National PHLS Reference Laboratory for antiviral drug resistance. Currently Deenan Pillay is Professor of Virology at University College London (UCL), UK, Head of the Research Department of Infection and Honorary Consultant Virologist at University College London Hospital (UCLH). He is Programme Director for Infection, Immunology and Inflammation at the National Institute for Health Research (NIHR) UCLH / UCL Biomedical Research Centre, UK and Programme Director for Infectious Diseases for UCL Partners. He is also a Senior Investigator for the NIHR. His research focuses on the biological and clinical implications of HIV drug resistance, and the molecular epidemiology of HIV. In addition, he works on international studies of HIV treatment rollout, and is Director of one of the five World Health Organization Specialist Reference Laboratories for HIV drug resistance.